ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside

Tyrosine Kinase Inhibitors (TKI) have significantly changed the landscape of current cancer therapy. Understanding of mechanisms of aberrant TK signaling and strategies to inhibit TKs in cancer, further promote the development of novel agents. ABT-869, a novel ATP-competitive receptor tyrosine kinas...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Zhou, Jianbiao, Goh, Boon-Cher, Albert, Daniel H, Chen, Chien-Shing
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2009
Gaiak:
Review
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2729745/
https://ncbi.nlm.nih.gov/pubmed/19642998
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-2-33
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak